Hypohidrotic Ectodermal Dysplasia Milia Treatment With Fractional Carbon Dioxide Laser and Laser-Assisted Drug Delivery of Triamcinolone

November 2023 | Volume 22 | Issue 11 | 1130 | Copyright © November 2023


Published online October 17, 2023

doi:10.36849/JDD.7650

Jessica Mineroff BSa, Jessica R. Dowling MDa, Nicole M. Golbari MDa, Todd Wechter MDa, Jared Jagdeo MD MSa,b

aDepartment of Dermatology, State University of New York, Downstate Health Sciences University, Brooklyn, NY
bDermatology Service, Veterans Affairs New York Harbor Healthcare System - Brooklyn Campus, Brooklyn, NY

Abstract
Hypohidrotic ectodermal dysplasia (HED) is a genetic disorder characterized by hypohidrosis, hypodontia, and hypotrichosis. Skin manifestations, including dyspigmentation and milia-like papules that coalesce into plaques, are difficult to treat. There is no cure for HED, therefore treatment is focused on managing symptoms and improving quality of life. There is limited evidence in the literature for safe and effective treatments improving HED-related facial skin aesthetics. The facial skin rashes caused by HED demonstrate an unmet clinical need in dermatology. Current therapies are limited to prevention methods such as keeping the skin cool by avoiding heat and applying topical moisturizers to help treat dry, pruritic skin. Herein we present a method for successful treatment of a 34-year-old African American male using fractional carbon dioxide CO2 ablative laser with laser-assisted drug delivery of triamcinolone 0.1% ointment that resulted in decreased milia-like papules, improved dyspigmentation, smoother skin tone, and high patient satisfaction.

J Drugs Dermatol. 2023;22(11):1130-1132    doi:10.36849/JDD.7650

INTRODUCTION

Hypohidrotic ectodermal dysplasia (HED) is a genetic disorder caused by mutations in one or more genes involved in embryonic ectodermal development that lead to hypohidrosis, hypodontia, and hypotrichosis.1 This disorder results from mutations in tumor necrosis factor-alpha (TNF-alpha) and ectodysplasin A (EDA) pathways.1 HED affects approximately 1 in 17,000 births and is most often X-linked, thus prevalence is higher in males.1 There is no cure for HED, so treatment is focused on managing symptoms and improving quality of life. 

Skin manifestations of HED can be particularly difficult to treat. Symptoms include dryness, ichthyosis, hypo- or hyperpigmentation, sparse and patchy hair, and milia-like papules that coalesce into plaques on the face.1 Milia-like eruptions in HED may be attributed to hypohidrosis, large sebaceous glands, or eruptive vellus hair cysts.2 Treatments are limited to keeping the skin cool by avoiding heat and applying topical moisturizers to help treat dry, pruritic skin.3

Clinical Features of a Hypohidrotic Ectodermal Dysplasia Patient
A 34-year-old African American male presented with a persistent rash on his face that began in childhood and had not changed. The rash was not painful, burning, or pruritic, but the patient complained of significant psychological distress due to the appearance. A physical exam revealed many monomorphic milia-like papules coalescing into plaques on the face with sparing of the perioral and periorbital regions (Figure 1). Additionally, there was sparse eyebrow and scalp hair and a prominent forehead. The patient declined a full-body skin exam but had no other dermatologic concerns and no other lesions were noted in the surrounding, observable areas. 

Medical history was significant for HED and multiple dental implants. The patient used adapalene gel on the face nightly